{"disease":{"id":"relapsed-non-hodgkin-lymphoma","name":"relapsed non hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06090539","title":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":308,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05746858","title":"Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05826535","title":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT03332017","title":"A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04970901","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"ADC Therapeutics S.A.","has_results":false},{"nct_id":"NCT07439653","title":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":155,"lead_sponsor_name":"TORL Biotherapeutics, LLC","has_results":false},{"nct_id":"NCT04718675","title":"A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":135,"lead_sponsor_name":"Kronos Bio","has_results":false},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06561425","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Galapagos NV","has_results":false},{"nct_id":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT04603872","title":"CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04134247","title":"Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT05618327","title":"Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05320640","title":"Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03245905","title":"Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06189391","title":"A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"MSD R&D (China) Co., Ltd.","has_results":false},{"nct_id":"NCT05768529","title":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","has_results":false},{"nct_id":"NCT04464590","title":"Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT02625480","title":"Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Kite, A Gilead Company","has_results":false},{"nct_id":"NCT05798897","title":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":79,"lead_sponsor_name":"Marker Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05050630","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":73,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT04609241","title":"CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT03623087","title":"SIMPLE Chemotherapy for NK Lymphoma/Leukaemia","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT07159906","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03755154","title":"Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":60,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT04923789","title":"A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT03505944","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":59,"lead_sponsor_name":"Nordic Lymphoma Group","has_results":false},{"nct_id":"NCT05420493","title":"Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Chongqing Precision Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05880043","title":"GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"GI Cell, Inc.","has_results":false},{"nct_id":"NCT06970496","title":"A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06565689","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Excyte Biopharma Ltd","has_results":false},{"nct_id":"NCT05842707","title":"Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Aibin Liang，MD，Ph.D.","has_results":false},{"nct_id":"NCT03263637","title":"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02384954","title":"QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Altor BioScience","has_results":true},{"nct_id":"NCT05006534","title":"Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06097455","title":"First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Fundacion Clinic per a la Recerca Biomédica","has_results":false},{"nct_id":"NCT07073833","title":"The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","has_results":false},{"nct_id":"NCT07502118","title":"NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Health Institutes of Turkey","has_results":false},{"nct_id":"NCT05564806","title":"Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT05370430","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"PeproMene Bio, Inc.","has_results":false},{"nct_id":"NCT06158386","title":"Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT04697940","title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Han weidong","has_results":false},{"nct_id":"NCT06082596","title":"Study of BEBT-908 in Subjects With Advanced Hematological Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"BeBetter Med Inc","has_results":false},{"nct_id":"NCT05008055","title":"Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07234045","title":"A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT07376642","title":"A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Suzhou Immunofoco Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT03403725","title":"MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Menarini Group","has_results":true},{"nct_id":"NCT06550141","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Marcela V. Maus, M.D.,Ph.D.","has_results":false},{"nct_id":"NCT07345741","title":"Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}